Department of Medicine DIMED, Surgical Pathology & Cytopathology Unit, University of Padua, 35121 Padua, Italy.
Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):159-69. doi: 10.1016/j.bpg.2013.03.009.
The mainstream carcinogenic processes involved within the gastrointestinal tract are characterized by phenotypic multistep progression cascades that eventually result in full-blown cancers. In this scenario, the understanding of the molecular dysregulations underlying the precancerous lesions is increasing but still remains incomplete. However, in recent years, the enthusiastic rise of innovative technologies (i.e., next-generation sequencing, high-throughput microarray analysis, mass spectrometry based proteomics) and the unexpected discovery of new classes of biomarkers (i.e., miRNA, long-noncoding RNAs) prompted new strength in the exploration of the accurate and comprehensive molecular characterization of premalignant and malignant neoplastic lesions. The challenge ahead lies in the reliable identification of disease progression-specific targets to enable molecular testing in the clinical management of the secondary prevention of gastrointestinal cancers.
胃肠道内涉及的主流致癌过程的特征是表型多步进展级联,最终导致完全癌变。在这种情况下,对癌前病变潜在分子失调的理解正在增加,但仍不完整。然而,近年来,创新技术(即下一代测序、高通量微阵列分析、基于质谱的蛋白质组学)的热潮兴起,以及新的生物标志物(即 miRNA、长非编码 RNA)的意外发现,为探索癌前和恶性肿瘤病变的准确和全面分子特征提供了新的动力。未来的挑战在于可靠地识别疾病进展特异性靶点,以便在胃肠道癌二级预防的临床管理中进行分子检测。